Literature DB >> 2540363

[Pharmacokinetic evaluation of fluconazole in healthy volunteers].

K Shiba1, A Saito, T Miyahara.   

Abstract

Fluconazole, a novel triazole antifungal agent, was studied for its safety and pharmacokinetics following single oral or intravenous dose to 8 healthy male volunteers. Dosages employed were 25 mg, 50 mg and 100 mg orally and 25 mg and 50 mg intravenously. With oral doses, peak plasma levels were achieved in 2 hours in all subjects, with maximum plasma levels of 0.53 microgram/ml at a dose of 25 mg, 0.92 microgram/ml at 50 mg and 1.88 micrograms/ml at 100 mg showing a clear dose-response. Plasma-half lives of the drug were about 31 hours in both oral and intravenous administrations. Its urinary recoveries were about 70% as given orally as well as intravenously. There was no difference between areas under plasma concentration-time curves (AUC) obtained with the 2 administration methods. No side effects nor abnormal clinical test values were reported with any subjects studied.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540363

Source DB:  PubMed          Journal:  Jpn J Antibiot        ISSN: 0368-2781


  5 in total

1.  Penetration of oral fluconazole into gynecological tissues.

Authors:  H Mikamo; K Kawazoe; Y Sato; K Izumi; T Ito; K Ito; T Tamaya
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 2.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 3.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

4.  Effect of fluconazole on theophylline disposition in humans.

Authors:  H Konishi; K Morita; A Yamaji
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

5.  Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model.

Authors:  Supavit Chesdachai; Radha Rajasingham; Melanie R Nicol; David B Meya; Felix Bongomin; Mahsa Abassi; Caleb Skipper; Richard Kwizera; Joshua Rhein; David R Boulware
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.